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Abstract
We study the strategic interaction between the pricing decisions of
a pharmaceutical firm and the reimbursement decisions of a government
agency which grants reimbursement rights to patients for whom new drugs
are most cost-eﬀective. If the reimbursement decision precedes pricing,
the agency only reimburses some patients if the drug’s private and pub-
lic health benefits diverge. This is, there are consumption externalities
and the variable cost of the drug exceeds the alternative’s. Contrarily, if
the firm can commit to a price before reimbursement, a strategic eﬀect
implies that by setting a suﬃciently high price, the firm can make the
agency more willing to reimburse than without commitment.
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1 Introduction
New drugs and medical devices are valuable goods that provide welcomed health
benefits. However, they are also very expensive. According to the OECD, phar-
maceutical costs are the major drivers of health care expenditures1. Given that
in most countries the consumption of medicines is subsidized,2 the growth in the
prices of new drugs has resulted in increases in public spending. In a situation
where resources are limited and there is competition for public funds, govern-
ments have had to find ways to rationalise the use and dissemination of these
new products. Agencies have been set up to decide which drugs are ”value for
money”. These agencies are constituted by committees of experts, who in con-
sultation with the diﬀerent parties (patients, providers and firms) decide which
drugs are cost-eﬀective. Some examples are: the National Institute for Clini-
cal Excellence (NICE) in the UK, Pharmac in New Zealand, Fasi in Austria,
the Pharmaceutical Benefits Advisory in Australia or the Commission of Trans-
parence in France. The decisions these agencies take are based on clinical and
economic evidence which is usually summarised in a cost eﬀectiveness analysis.
The analysis measures the health benefit associated with increasing access to a
drug, places a monetary value on this benefit and compares it with the provi-
sion cost of provision. The analysis may identify the group of patients for whom
the drug will result in benefits that compensate the cost as the same drug may
result in diﬀering health benefits for patients, depending on the severity and
strand of the illness and the possibility of side eﬀects. For example, in NICE’s
published guidelines, one can see that sometimes a specific group of patients is
selected based on a threshold of a diagnostic test, such as in the case of drugs for
obesity, diabetes or Alzheimer’s disease, or in other occasions a specific group
is selected based on the description of certain symptoms. In March 2001, NICE
considered Orlistat, a drug which fights obesity. The decision was that the drug
should be prescribed to patients who had lost at least 2.5 kilos in weight by
dieting and who either had a body mass index of 30 kg/m2 or a body mass
index of 28 kg/m2 and the presence of significant co-morbidities. In the report,
one can find considerations about the 1998 direct costs and indirect costs to the
NHS associated with obesity, a summary of the results of several clinical trials
of Orlistat, and a cost eﬀectiveness analysis which estimates the total annual
drug costs of implementing the guidance, based on the current drug price.
The impact of a favourable cost-eﬀectiveness analysis varies in each jurisdic-
tion. It usually implies that national guidelines are issued for public providers
to encourage the use of the drug. In occasions, a positive result will directly
imply that the drug is listed for reimbursement. For example, in the UK, since
January 2002, the NHS is obliged to provide funding for NICE approved drugs
1For example, pharmaceutical expenditure has doubled in real terms in Sweden and Aus-
tralia between 1990 and 2001, and increased by more than 70% in Canada, Finland, Ireland,
and the US. See OECD, 2004.
2Reimbursement policies vary from country to country. In the UK for example, patients
must pay £6.40 per prescription. In Austria patients pay a fixed amount and a fraction of the
price of the drug. In France patients pay 0%, 65% or 35% of the price of the drug, depending
on the drug’s class.
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after 3 months of the publication of the listing decision. Sometimes the eﬀect of
a positive result of the test on the listing of the drug for reimbursement will not
be as immediate, but will feed in the considerations made in the reimbursement
decision.
We model the strategic interaction between an innovator firm (monopoly)
and a decision maker who chooses whether to list the drug for reimbursement
and if so, which patients should be subsidized. The decision maker does this
by comparing the excess health benefits and the excess costs of enlarging the
patient group with reimbursement rights. The aim of this research is two-fold.
Ultimately we want to understand what are the eﬀects of the listing decision on
the costs of provision (public and private3) and the dissemination of the drug
in the presence of a strategic firm. Yet, to do this, we must study how the
listing decision (and its eﬀects) depends on: the quality of the new drug with
respect to existing treatments, the existence of externalities associated with the
consumption of the drug and the extent to which those are considered by the
agency,4 the possibility that the firm commits to a price before the agency makes
a listing decision5 and the possibility that doctors prescribe the drug privately
(aside the public provider) generating an ”unsubsidized” demand for the drug.6
We show that if the reimbursement decision precedes the pricing decision, the
agency only reimburses some patients if the private and public health benefits
from the new drug diverge. That is, when (i) there are large externalities of
consuming the drug and (ii) the diﬀerence in variable costs between the new drug
and the alternative treatment is large. Alternatively, if the firm can commit to
a price in advance of the reimbursement decision, we identify a strategic eﬀect
which implies that by committing to a high price ex ante, the firm can force
a listing outcome and make the agency more willing to reimburse than in the
absence of commitment.
Whilst health economists and managers have paid a lot of attention to the
measurement of the benefits of drugs and the placement of their monetary value,
the analysis of the costs of provision has been highly neglected. With this work,
we point out that the cost of provision will depend on how drug prices are set, as
this will frame the ability of firms to react to listing. Hence, we must understand
how firms react to and anticipate the news that their drug is being listed for
reimbursement and derive the due eﬀect on market variables.
From an academic point of view this research is also interesting as the special
3Patients also directly contribute to the financing of their consumption.
4There are several sources of externalities. They can be due to the nature of the disease- for
example infectious. They can also occur because of knock on eﬀects on the costs on the pro-
vision of health care, families and social services budgets. For example a higher consumption
of the drug may result in fewer hospitalizations.
5For example in the UK, the 1999-2004 Pharmaceutical Price Regulation Scheme which
applies to all branded licensed NHS medicines implies that pharmaceutical firms can initially
choose the price at which they introduce a drug in the market. However, after this, price
changes must be approved by the Department of Health. This approval is granted only if the
company can proof that its return on capital is below 8.4% (PPRS 2005). See publication in
the Department of Health website.
6 In most countries, drugs can be prescribed by private health care providers and be bought
by patients who then benefit from no subsidy.
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feature of these decisions is that they are decisions by which ”the government”
chooses to discriminate against a group, which are not based on income levels
but rather on how eﬀective the subsidized product is on the welfare of the group.
This is the special feature of our model. The impact of government agencies’
decisions to list medicines for patient reimbursement is an under-researched
area which has focussed on reimbursement for low income patients rather than
patients with high medical needs (e.g., Scott Morton, 1997). Therefore, we
concentrate on decision making that is based on medical grounds, focusing on
patients´ distinct medical needs, rather than on income levels. This novelty is
crucial and feeds in through the results. However, it implies that our paper is
most relevant for situations where there is limited income heterogeneity within
the patients of an illness.
Our paper belongs to the small literature on drug formularies which analyzes
health need based prioritization. Formularies list the drugs which consumers are
to be reimbursed for, and, by exclusion, the drugs oﬀ the reimbursement list.
They have been used by private (such as American HMOs) and public providers
(such as European public providers) to limit their expenditure on drugs. Our
paper analyzes how the existence of a drug formulary may aﬀect the prices
of a new drug. The works of Olmstead and Zeckhauser (1999) and Borrell
(2003) are directly related to this paper. Olmstead and Zeckhauser (1999) show
how menu setting techniques can be used to design optimal formularies, in
recognition that patients are free to choose the drugs they consume. In their
setting, an optimal formulary maximizes the health care benefits of patients
given exogenously set prices for drugs and a budget constraint. They focus on
the problem of encouraging ”eﬃcient consumption” when drugs have diﬀering
eﬀects on patients who are free to choose. Our object of analysis is diﬀerent, as
we focus on the impact that formularies might have on price setting, (this is in
our setting prices are endogenous), and also because we address the issue that
institutions implement restrictions on patient choice.
Olmstead and Zeckhauser (1999) describe the main criticism on formularies
as items that ”often include only those drugs that are cost eﬀective for the
average patient”7. This refers to the fact that committees typically examine
these decisions by grouping patients according to their disease and by grouping
drugs according to their therapeutic class. Nowadays it is possible to make
finer definitions within a patient group, in accordance to diagnostic tests and
others, and to place more sophisticated restrictions on the reimbursement of
the drug, which our paper addresses. Borrell (2003) also studies the impact of
the existence of drug formularies on drug prices. However, his paper reflects
a mature market were drugs are horizontally diﬀerentiated a la Dixit-Stiglitz
and listed for reimbursement. In his paper, an ”exogenous” threat that drugs
are de-listed can be diminished by reducing the price.8 We consider that such
paper is not suited to describe the interaction between innovators competing
with lower quality oﬀ-patent products.
7Olmstead and Zeckhauser (1999), page 6.
8Borrell (2003) does not model the decision making of the formulary commitee as pursuing
an objective function.
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There exists an early and relatively extensive literature on the determinants
of the prices of new drugs, which is reviewed in the introductory section of Lu
and Comanor (1998). The literature describes two possible pricing strategies:
penetration pricing by which the initial price is low and then increases, and
skimming pricing, the opposite. Its theoretical findings relate to the theory of
signalling of quality through prices, with contributions of Schmalensee (1982),
Shapiro (1983) and Bagwell and Riordan (1991) between others. Lu and Co-
manor (1998) provide empirical evidence that price skimming takes place when
the new drug is a substantial therapeutic improvement on existing drugs. We
ignore these signalling issues on the pricing of the new drug. The reason for
this is that the role of the agencies mentioned is to establish precisely which
drugs are cost eﬀective and to disseminate this information. The measurements
of the benefits and the ”quality” of the drug are made available to patients and
providers, which mitigates the need for signalling. Instead, we concentrate on
the strategic interaction between the pricing decision and the listing decision-
focussing on the later as a determinant of the prices of new drugs.
Our paper models the interaction between the listing decision of an agency
and the drug price decision of a monopoly as a multiple stage game. We consider
two alternative sequences of events. The first timing, which we refer to as ’no
price commitment’ considers a situation in which the agency decides first, which
consumers have reimbursement rights and then, the firm chooses the drug’s
price. In an alternative timing, which we refer to as ’price commitment’, the
firm can commit to a price in advance of the agency’s decision.
The choice of the first timing underlines the initial motivation of the paper,
to analyze how firms react to coverage news by changing prices. In analyzing
this we also assess what would happen if agencies internalized in their decision-
making the future market impact. Do agencies actually take future price setting
behaviour of firms when they decide whether to list a drug for reimbursement?
This is a diﬃcult question to answer, as in most countries these decisions are
not transparent. However, one would expect them to do so, and it is therefore
important to understand what happens if they do.
Secondly, it is also important to understand what happens if firms can com-
mit to their prices before the listing decision takes place as a first-instinct remedy
to a price increase which responded to a listing outcome would be to ask the
firm to commit to a price ex-ante. Hence, we explore this possibility in our
model with price commitment. This is also relevant as in some countries, firms
have ways to commit to their prices.
A last word of caution is that this work is as a stepping stone of a larger
research project. Health care provision is highly jurisdiction specific. Because
of this, any model of the health care industry suﬀers from the caveat that it will
necessarily not apply everywhere. As we will discuss, we have tried to overcome
this problem by making the benchmark model as general as possible in so that
it would still have interesting results and by pinning down what would be a
worst case scenario for reimbursement.
Section 2 presents the main features of the model. Sections 3 provides the
solution to the Agency’s reimbursement problem and the firm’s pricing problem
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when the firm can not commit ex ante to a price. Section 4 extends the analysis
to the situation where the firm can commit to a price before the Agency decides
on listing. Section 5 compares the two outcomes. Section 6 discusses the gener-
ality of the model and the sensitivity of our results to its assumptions. Section
7 concludes.
2 The model
We model the strategic interaction between a pharmaceutical firm producing a
new drug and a government agency that decides whose consumption should be
subsidized.
The pharmaceutical firm launches a new drug of quality q, q > 1. This drug
is patented and the only supplier is the firm, which acts as a monopoly. The
marginal cost of production of the drug is constant and equal to c. Patients
diﬀer in the improvements of health they derive from consuming the drug. In
other words, the eﬀectiveness of the drug depends on the patient type. By
taking the new drug, patient type θ benefits from an improvement in health of
θ · q. We assume that θ is uniformly distributed in the interval [θ, θ].
There is a second best alternative treatment which yields an improvement in
health to type θ of θ only. This alternative is not listed for reimbursement and
is supplied by a competitive fringe of firms at a given price of c.9 We assume
that θ > c, which implies that all patients will either purchase the innovation
or the alternative treatment10.
We model a government agency with the power to decide which patient
types can benefit from an exogenously determined subsidy on the price of the
new drug.11 We define the amount of patients with reimbursement rights as
the coverage level. An crucial feature of our model is the assumption that the
agency can treat patient types diﬀerently. This is the agency will select the
coverage level according to the drug’s eﬀectiveness on patients.
The agency chooses the coverage level so as to maximize its objective func-
tion. This objective function captures some of the observed features of the
decision processes in a number of health agencies. In addition, the objective
function serves as a benchmark in the sense that it provides a worst case sce-
nario for reimbursement. First, the agency’s objective function will not include
the monetary costs borne by patients or the firm’s profits.12 This aims to re-
flect the absence of such considerations in Nice’s reports, and also implies that
our model does not favour a high level of coverage. In her decision making,
9We can interpret this price as the cost of production of an alternative drug or as the cost
of an alternative treatment for the patient. For example, an alternative to taking an obesity
drug is dieting.
10Cabrales (2002) uses a similar model of diﬀerentiation to study the eﬀects of price ceilings
on the provision of quality.
11 Subsidies are subject to general law and can not be changed for specific drugs. We do not
model the subsidy level in our analysis.
12Note that this implies that the agency is not maximizing a welfare function.
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the agency does not internalize the fact that as the coverage increases, profits
increase and costs to patients decrease.
In taking her decision, the agency considers the public costs of reimburse-
ment, the private health benefits from the consumption of the diﬀerent available
treatments- new and old and an externality which is exclusively associated with
the dissemination of the new drug. We model the externality as a per capita
externality. We may interpret it as the public health benefits related to the
consumption of the drug13 or the savings accrued by the health care system in
terms of forgone on-going costs associated with the distribution of the drug.14
Taking the stand of Olmstead and Zeckhauser (1999), who describe that
”the goal in health care, at least implicitly, is to spend treatment dollars where
they will produce significant benefits”15 , we assume that the agency decides to
reimburse the patients for whom the drug is most eﬀective, i.e. those charac-
terized by a larger θ. More specifically, the agency chooses a threshold θL, such
that all patients with θ > θL benefit from the subsidy. Then, the coverage level
is θ − θL. The objective function of the agency is described below:16
θZ
θL
θ · q+
θLZ
θ
θ−
θZ
θL
(P −S) + v · (θ− θL), (1)
where P is the full price of the drug, S is the price paid by patients with
reimbursement rights, and v is the per capita externality.
We consider a general form for the consumer price: S = τ + η · P , with
τ/ (1− η) ≤ c. Here, τ represents a flat rate and η a proportional rate. Conse-
quently, the cost per dose for the public funds is: P − S = (1− η)P − τ .
The pharmaceutical company chooses the drug’s price. The firm can freely
choose the price but cannot price discriminate between patients with and with-
out reimbursement rights17 . Patients with no reimbursement rights can pur-
chase the new drug at full price if they wish to.18
13The existence of such externalities becomes evident in certain conditions like infectious
diseases, serious mental illnesses and conditions involving long term incapacity, but, in general
most medical conditions may in principle have an impact over labour productivity (see e.g.
Francis (1997), Krieg (2002) and Laux (2000)).
14Due to the reduction in hospitalization episodes, specialist needs and other costs.
15Olmstead and Zeckhauser (1999), page 2.
16Assuming that all patients with reimbursement rights purchase the drug and that patients’
with no reimbursement rights do not purchase the drug.
17This is the government implements no constraint on the firm’s initial prices. This reflects
the UK and US case. In other countries, there is bargaining on price between the government
and the firm (in France the Comite Economique du Medicament will negotiate the price and
the volumes of reimbursed drugs, or in new Zealand, Pharmac will make the reimbursement
decision contingent on some agreed price). The eﬀects of reimbursement on pricing decisions
in a setting with bargaining have been studied by Jelovac (2002), where she finds that higher
subsidies reduce prices when prices are negotiated.
18All of these assumptions also reinforce a ”worst case scenario for coverage”. The fact that
the firm is unable to price discriminate between patients with reimbursement and without
reimbursement rights restricts the ability of the firm to induce listing by increasing the price
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In the following two sections, we analyze two alternative timings of events.
First, we consider the case in which the coverage decision precedes the firm’s
pricing decision. Second, we analyze the game where the firm is able to com-
mit to a price before the coverage decision takes place. We find the subgame
perfect equilibrium of these two games and compare their outcomes. All of the
computations for the results can be found in a mathematical appendix.
3 Benchmark: The game with no price commit-
ment
In stage 1 the agency decides the coverage level θ − θL, in stage 2 the firm
chooses its price and in stage 3 patients make their consumption decisions. We
represent this with following timeline:
agency firm patients−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→
↓
coverage
↓
price
↓
consumption
3.1 Stage 3: Patient’s consumption decisions
There are two groups of patients: those with reimbursement rights (if θ is such
that θ > θL), and those without reimbursement rights (if θ is such that θ < θL).
Patients with reimbursement rights buy the new drug if their utility (θ · q − S)
exceeds the utility they would obtain from the alternative treatment (θ − c).
The indiﬀerent consumer is given by: θR = S−c∆q ,where ∆q = q− 1.19 Similarly,
for patients with no subsidy the indiﬀerent consumer is: θF = P−c∆·q . Hence, the
demand function for the new drug is:
D(P ) =
⎧
⎪⎨
⎪⎩
θ − θR; if P > ∆q·θL+c−τη θL
θ − θL; if ∆q·θL+c−τη θL ≥ P > ∆q · θL + c
θ − θF ; if P < ∆q · θL + c.
(2)
Figure 1 depicts demand function for the new drug at a given threshold θL.
(insert figure 1 around here (demand graph))
The demand curve has kinks as its elasticity depends on whether consumers
have access to the subsidy or not. As indicated in Figure 1, the demand function
is more inelastic in the range where the price subsidy applies. It also has a range
where it is completely inelastic, corresponding to prices such that θR < θL <
θF .
for the non-reimbursed. Similarly, that patients with no reimbursement rights can purchase
the drug privately reduces the need for a subsidy.
19Note that there is a divergency between consumer choice and the choice desired by the
agency who would hope that patients internalized the externality in their decisions. This would
be the case if the equation driving patients behaviour was: (θ · q + v − S) > (θ − c) .
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Definition 1 πR = (P − c)(θ − θR) is the profit function when all patients
have reimbursement rights (full coverage: θL = θ) and θ
R∗ = ∆qθ+ηc+τ−c2∆q is
the indiﬀerent consumer that maximizes πR. Similarly πF = (P − c)(θ − θF )
is the profit function when no patients have reimbursement rights (θL = θ) and
θF∗ = ∆qθ+c−c2∆q is the indiﬀerent consumer that maximizes πF .
Note that as long as the threshold θL is larger than θ
R∗, θR∗ will be the
indiﬀerent consumer driving demand for the new drug. Similarly, θF∗ will be
the indiﬀerent consumer provided that θF∗ falls below θL.
3.2 The firm’s choice of price
In this section, we characterize the price that maximizes the firm’s profits, P ∗.20
The following proposition summarises the main result:
Proposition 2 There are three cases:
(i) High coverage. If θL < θR∗, then P ∗ = PR = 12η (∆qθ + c + ηc − τ),
and
³
θ − θR∗
´
consumers purchase the drug. This is only some consumers with
reimbursement rights purchase the drug.
(ii) Intermediate coverage. If θR∗ < θL < α, then P ∗ = PL =
θL∆q+c−τ
η
and θ − θL consumers purchase the drug: All consumers with reimbursement
rights purchase the drug.
(iii)Low coverage. If θL > α then P ∗ = PF = 12(∆qθ+ c+ c) and and θ−θ
F∗
consumers purchase the drug. Even consumers with no reimbursement rights
purchase the drug.21
insert figure 2 around here (profit graph)
Figure 2 provides a graphical representation of the result. The thicker line
illustrates the maximum value of the firm’s profit as a function of the reimburse-
ment level set by the agency, π(θL). The two other functions represent πR and
πF ,as defined above.
To understand proposition 2, it is worth acknowledging that the subsidy
creates a wedge between the willingness to pay of consumers with reimbursement
rights and the willingness to pay of consumers with no such rights. This implies
that in order to serve consumers with no rights, the firm must reduce its price
substantially (so as to make the indiﬀerent consumer θF∗ fall below θL ). It
will only pay to do so if the number of consumers with reimbursement rights is
suﬃciently low. The shape of the thicker curve in Figure 2 can now be explained.
20 In the appendix we find the local maxima in each of the demand regions (interior or corner
solutions) and then we compare those maxima to obtain a global maximum.
21The value of α,
?
α > θF∗
?
, can be found in the Appendix. It is defined as the value of
θL such that πF
?
θF∗
?
= πR (θL) .
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If coverage is large θL < θ
R∗, the firm can reach the highest level of profit π∗R
as all the consumers who the firm serves have reimbursement rights. However,
if coverage is smaller (θR∗ < θL < α), it pays for the firm to adjust her prices
(setting them high) so as to serve only those consumers who have reimbursement
rights. Yet, there is a level of coverage (θL = α) below which it is not profitable
for the firm to take notice of the small group of consumers with reimbursement
rights when setting prices. In this range, the best the firm can do is to lower
prices so that consumers with no rights purchase the drug as well.
The impact of listing on the access to the new drug will depend on the
level of coverage. If θL is suﬃciently high (θL > α), the firm will decide to serve
θ−θF∗ patients, where only a few (θ−θL ) will benefit from the subsidy. In this
case, listing the drug will not result in a larger number of patients consuming
it. Only θ − θF∗ consumers would consume the drug, as if no subsidy existed.
For intermediate levels of coverage, θF∗ < θL < α, listing has a perverse
eﬀect. Comparing this with the situation with no listing: the prices and the
costs to the public funds are higher and only a few (θ−θL) individuals purchase
the drug, as opposed θ − θF∗ (with θ − θL < θ − θF∗).
Finally, with a high coverage level θ < θL < θ
F∗, listing results in an increase
of the public costs but at the same time there is a larger consumption of the
new drug. Which eﬀect dominates will determine whether listing the drug is
the best option for the agency or not.
3.3 The agency’s coverage decision
Given Proposition 2, it is clear that in choosing the coverage level, the agency in-
directly selects the price regime. Here, we identify the agency’s optimal choice.
We first state the objective function for the agency, which, consistently with
the analysis for the profit function, has a diﬀerent form for each of the three
coverage levels described in Proposition 2:22
OF (θL) =
⎧
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
OF1 =
θR
θR∗
qθdθ +
θR∗R
θ
θdθ −
θR
θR∗
(PR − SR) dθ + v(θ − θR∗)
if θL < θ
R∗
OF2 =
θR
θL
qθdθ +
θLR
θ
θdθ −
θR
θL
(PL − SL) dθ + v(θ − θL)
if θR∗ < θL < α
OF3 =
θR
θF∗
qθdθ +
θF∗R
θ
θdθ −
θR
θL
(PF − SF ) dθ + v(θ − θF∗)
if θL > α.
(3)
where Si=τ + ηPi.
Finally, the welfare of not listing the drug is:
22An evaluation of the last expression can be found in the Appendix.
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OFNL =
θZ
θF∗
qθdθ+
θF∗Z
θ
θdθ+v(θ−θF∗) = q θ
2
2 −
θ2
2 −∆q
(θF∗)
2
2 +v(θ−θ
F∗). (4)
Note that the welfare of not listing coincides with the welfare achieved when
there is no coverage θL = θ.
Proposition 3 If θF∗ < θL < θ, the agency does not reimburse any patients.
Since granting subsidies is costly, the agency only wishes to do so if there are
added (private and public) health benefits. These added benefits only accrue if
listing the drug results in a larger consumption. However, if θL > θ
F∗, listing the
drug does not increase demand. As already explained, if θF∗ < θL < α, demand
falls as a result of listing, and if α < θL < θ, demand is determined by θ
F∗ and
is unaﬀected by reimbursement. Since not reimbursing allows the agency to
economise on costs, in these regions not listing is preferred by the agency to any
coverage. In other words, from the point of view of the agency, there is no point
in introducing a subsidy which will be made available to patients who would
consume the drug even if that subsidy did not exist.23
As a consequence, we only must check whether the agency would rather list
the drug for reimbursement and set θL < θ
F∗ or not list the drug at all. To
confirm this we characterize the shape of the agency’s objective function. There
are two forms for this function as depicted in Figures 3 and 4.24
(insert figures 3 and 4 around here)
The explanation of these shapes is related to the impact of listing on the
demand for the drug. If there is no coverage
¡
θL = θ
¢
, an increase in the level
of coverage (a reduction in θL) will initially reduce the agency’s payoﬀ since,
as it will not raise the consumption of the new drug and will only increase the
public costs (this explains the shape of OF3). When θL = α is reached, there
is a downwards discontinuity in the OF function. It is due to the fact that at
this point, the firm prefers to set higher prices and serve only the consumers
with reimbursement rights rather than setting lower prices to serve θ − θF∗
consumers. The shape of the function for decreases in θL beyond α will depend
on the strength of the subsidy. If the subsidy is low, further increases in coverage
will actually increase the payoﬀ to the agency (see OF2 in Figure 3). For high
subsidies further increases in coverage may have an initial negative impact on
the payoﬀ to the agency (see OF2 in Figure 4). In this range, the added health
benefits of a larger coverage can not compensate for the increase in public costs.
23 If the agency cared about economic welfare (which would include private costs and the
firm’s profit) there would be ”more” listing. The reason is that when the agency does not list
the drug, this results in larger costs for patients and/or smaller profits for firms. Given our
specification of the agency’s objective function, these negative eﬀects are not internalised by
the agency’s decision who decides not to list the drug excessively from a welfare point of view.
24 See Appendix for a formal proof of the shape of these figures.
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Finally, increases in coverage beyond θ − θR∗ will not have any impact on the
agency’s payoﬀ as for those levels demand for the new drug is fixed at θ − θR∗
(this explains the shape of OF1).
In conclusion, the only global maximum candidates are either setting θL = θ
to achieve OFNLor setting any θL ∈ (θ, θR∗) to achieve OF1 (θL). The decision
turns out to be a binary one. We name the two options not listing (θL = θ) and
listing (θL ∈ (θ, θR∗)). The expression for the ”incentive to list” is the diﬀerence
in payoﬀs between listing and not listing:25
OF 1 (θL)−OFNL=
∆q
2
·
µ³
θF∗
´2
−
³
θR∗
´2¶
+v(θF∗−θR∗)− (PR−SR) · (θ−θR∗). (5)
Since θF∗ > θR∗, the expression shows that the health benefits of listing
exceed those of not listing, but as well that listing the drug is costly in terms of
public funds. The balance of the health and the cost eﬀects determines whether
the agency decides to list.
Moreover, we deduce that ∂OF1(θL)−OF
NL
∂θF∗ > 0. In other words, as the num-
ber of people who would buy the drug if it weren’t subsidized grows, the excess
benefits of listing the drug for reimbursement are smaller and the incentives to
list diminish. Indeed, the agency subsidizes the drug to supplement the lack
of private demand. This is the case when θF∗ is large as then most patients
would not buy the drug in the absence of a subsidy. This is the case where it
might be in the interest of the agency to list the drug for reimbursement and
set θL < θ
F∗.26
3.3.1 Comparative statics on the incentive to list, OF1 (θL)−OFNL
In this section, we check how OF1 (θL)−OFNL varies with v, c, c, θ and ∆q.
Lemma 4 The incentive to list is more likely to be positive for large v and c,
and for small c.
A larger value of the externality results in a larger diﬀerence between the
objective function in regime 1 and the objective function with no reimbursement.
The eﬀect is intuitive. With reimbursement more people access the drug and as
the value of v grows, the diﬀerence between the objective functions grows.
As c− c grows, the diﬀerence between access to the drug with and without
listing increases. As a consequence, the diﬀerence between the values of the
25Despite the ”incentive to list” terminology, readers must be warned the readers aware
that this is not a marginal incentive. The decision of the agency at this stage is binary: either
to list or not to list.
26The derivative with respect to θR∗ does not always have the same sign. The reason is
that as θR∗ grows the diﬀerence between the health benefits of listing the drug or not listing
the drug are smaller, but it is unclear whether the costs of listing increase or not: on the
one side, a larger θR∗ is associated with a large price for the drug and a smaller public cost
per dose, yet fewer patients are reimbursed and this might counterbalance the previous eﬀect.
The overall outcome is ambiguous.
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objective functions should increase. However, the eﬀect of the cost diﬀerence
on the diﬀerence in public costs between regimes is unclear. Given the sign of
the derivative we can guarantee that even if public costs increase with listing,
this adverse eﬀect is overcome by the larger health benefits.
Lemma 5 There exists a η∗ ∈ (0, 1) such that if η < η∗, we obtain that the
incentive to list is decreasing in ∆q and θ. If η > η∗ then the incentive to list
is increasing in θ.
An increase in ∆q has a number of eﬀects on the decision to list. On the
health side, quality will have a positive direct impact on the incentives to list
as for a given number of extra patients treated with reimbursement the benefits
will be larger. Yet, the number of patients treated is not fixed, and there
is an indirect negative eﬀect through the changes in regime demands that a
higher quality results upon. With higher quality more consumers purchase the
drug with no listing, and the excess access to the drug with reimbursement
is smaller.27 Moreover changes in ∆q also aﬀect the public costs of listing.
The increase in ∆q will have a positive impact of the unit price paid by the
agency: ∂(PR−SR)∂∆q > 0 and in this way a positive impact on the listing costs
(fewer incentives to list). However, if ∂θ
R∗
∂∆q ≥ 0 this eﬀect might be partially
compensated by a reduction in the number of patients who have reimbursement
rights. The total cost eﬀect can therefore be ambiguous. However, in the case
where subsidies are large, the overall eﬀect is that a higher quality reduces the
incentives to list.
The final lemma in this section reinforces the idea that mainly it is the wedge
between private willingness to pay and public willingness to pay (determined by
the externality) that creates a ”public” need to list the drug for reimbursement.
Lemma 6 If 0 < η < 1, v = 0, c = 0 and τ = 0 and c < 2∆qθ?
η+
√
7η2+2η
?we obtain
that OF1 (θL)−OFNL < 0. This is the agency opts for not listing.28
4 The game with price commitment
In this section, we analyze the outcome of the coverage decision in the case
where the firm can commit to a price in advance of the agency’s decision. In
this game, in stage 1, the firm chooses the price, in stage 2, the agency chooses
the coverage θ − θL and in stage 3 consumers make purchasing decisions. For
27Whether there are more consumers purchasing the drug with listing depends on the sign
of ∂θ
R∗
∂∆q . However, given that
???∂θF∗∂∆q
??? >
???∂θR∗∂∆q
??? even in the case where ∂θ
R∗
∂∆q
≤ 0, we find that
listing the drug results in a smaller access with higher quality. The reason is that consumers
purchasing decisions are more reflective of quality when consumers pay the full price.
28Note that if ∆qθ > 2 then c < 2∆qθ?
η+
√
7η2+2η
? , is satisfied for all η, with η ≤ 1.
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simplicity, we focus on the case where v = 0, c = 0 and τ = 0, which allows a
direct comparison with Lemma 6.29
firm agency patients−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→
↓
price
↓
coverage
↓
consumption
Note that, θR = ηP∆q and θ
F = P∆q and that in this section the price P is
an ex ante commitment and therefore, ex post the price does not change, and
does not depend on the agency’s decision. The assumption that the firm can
commit to a price generates a substantial diﬀerence in the outcome of the game.
It turns out that, if the firm can commit to a price before the agency decides
on coverage level, it can actually induce listing by choosing a suﬃciently high
price.30
4.1 The agency’s coverage decision
In the last stage, for any given choice of the firm P , there are three possible
choices of θL:
OF =
⎧
⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎩
OF1 =
θR
θR
θqdθ +
θRR
θ
θdθ − (1− η)P (θ − θR) if θF > θR > θL
OF2 =
θR
θL
θqdθ +
θLR
θ
θdθ − (1− η)P
¡
θ − θL
¢
if θF > θL > θ
R
OF3 =
θR
θF
θqdθ +
θFR
θ
θdθ − (1− η)P
¡
θ − θL
¢
if θL > θ
F > θR
(6)
We first find the choice of θL that maximizes the objective function of the
agency, denoting it by θ∗L. This entails finding the local maxima for each of
the three regions and comparing them. Figures 5 and 6 show the shape of the
objective function and indicate the candidates for global maximum.
(insert figures 5 and 6 around here)
The intuition for these shapes is the same as in section 3. The change in the
timing of the game only aﬀects the shape of OF2. For a low subsidy (η > 1/2),
reductions in θL will have a positive eﬀect on the objective function of the
agency. In this range (see Figure 5) listing increases the consumption of the
new drug by (θF −θL) individuals. This positive impact is only partially oﬀ-set
29 In an extended version of the paper we show that the results of this section are qualitatively
very similar to the results that one would obtain with price commitment if τ > 0 and η = 0.
However, we can not directly compare the solution of this case with price commitment with
the solution with no price comitment. In the absence of price commitment if η = 0 the profit
maximization problem of the firm is unbounded as demand is fixed.
30 In the UK, such commitment can be achieved because of the way in which pharmaceutical
prices are regulated. According to the Price Regulation Scheme initially the firm is free to
choose a price for the drug, but subsequent changes of price (especially price raises) need to
be approved by the Scheme. Very few changes have been approved.
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by the negative eﬀect of the increase in the public cost, as the subsidy is low.
As a result of a larger coverage there is an increase in the OF . Contrarily, in
the case of high subsidies (η < 1/2), the cost eﬀect dominates the access eﬀect
if θL is low enough: when θL > θ
ˆ, OF2 is decreasing in θL (see Figure 6).
Hence, the optimal coverage level, θ−θ∗L, depends on the level of the subsidy.
With a low subsidy (η > 1/2) there might be no listing (θ∗L = θ) or listing with
θ − θR patients who purchase the drug (if θ∗L < θR). With a high subsidy
(η < 1/2) there can be no listing (θ∗L = θ) or listing where θ − θ∗L patients
purchase the drug with θ∗L > θ
R.
Proposition 7 If η > 1/2 and P > 2∆qθ1+3η or η < 1/2 and P > P
LIM =
2(1−η)∆qθ
2+η2−2η , the agency lists the drug for reimbursement. Otherwise she does not.
Proposition 7 states that, by setting a suﬃciently high price, the drug com-
pany can guarantee a listing outcome. At first glance, this might seem counter-
intuitive because, as the price rises, the unit cost of listing grows. However, it
is also true that as the price rises the diﬀerence between the health benefits of
listing and not listing grows. The latter eﬀect of a price increase on the excess
health benefits of listing exceeds the former eﬀect on the costs of listing. There-
fore, by committing to a high price, the firm can ”threaten” the agency with a
very small level of access to the drug in the case where there is no reimbursement
and force a listing outcome.
4.2 The firm’s choice of price
In this setting the firm chooses the price taking into consideration the agency’s
response. Clearly, low prices result in no coverage, and high prices result in
some coverage. What matters for the choice of the optimal price P ∗, is the
comparison of the profits of each situation.
As we have established, high prices induce the agency to list. Since coverage
raises the firm’s profit, normally the monopoly will choose ”high prices” in order
to achieve a listing outcome. The only exception to this is the case where, to
force a listing, the firm needs to distort the price upwards excessively- this is,
the distortion results in a profit smaller than the profit of no listing.
4.2.1 Low subsidies (η > 1/2)
If listing occurs, the firm positions herself in πR as opposed to πF in Figure 2.
This does not directly imply that profits are larger with listing as this really
depends on how large is the price needed to induce listing. Yet, the following
proposition establishes that with low subsidies, the firm can chose the price that
maximizes πR and that this price is suﬃciently large so that the agency lists
the drug.
Proposition 8 If η > 1/2, the firm sets P ∗ = ∆qθ+ηc2η ,
31 which yields profits:
31Note that P∗ = PR for c = 0 and τ = 0.
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π∗R =
1
4η∆q (∆qθ−ηc)2, the drug is listed for reimbursement, and the demand for
the new drug is (θ−θR∗). All consumers who purchase the drug are reimbursed.
Recall that lemma 6 tells us that with no price commitment and for c <
2∆qθ?
η+
√
7η2+2η
? the drug would not be listed for reimbursement. Here, with c = 0
and price commitment listing takes place. The reason is that with such high
price and in the absence of a subsidy the demand for the drug is too small. On
the face of such event the agency lists.
4.2.2 High subsidies (η < 1/2)
With high subsidies the result is not as clear cut as Proposition 8. There are cir-
cumstances where it is in the firm’s interest to induce listing, and circumstances
where this is not true.
With high subsidies if the drug is listed, the firm’s profits are: (P−c)
³
θ − (1−η)P∆q
´
.
These profits achieve a maximum value of 1−η4∆q
³
∆qθ
1−η − c
´2
at P+ = c2 +
∆qθ
2(1−η)
and θ+ = ∆qθ+(1−η)c2∆q . This value is larger that the profit when there is no list-
ing. Therefore, if P+ is high enough to induce listing, the firm will set this price
and listing will take place (part 9.1 in the following proposition).
However, there will be situations where P+ is too small to induce listing
(see part 9.2 in the following proposition). In such cases, to strategically induce
listing, the firm will need to distort upwards the optimal price P+. In some of
these cases, it will be better for the firm not to do so as the price distortion is so
large that the resulting profits are smaller than without listing. The following
proposition presents the conditions under which the firm will induce listing.
Proposition 9 For η < 1/2
9.1. If c > c∗ = ∆qθ(2+3η
2−6η)
(1−η)(2+η2−2η) , P
∗ = P+. The drug is listed for reimburse-
ment and
¡
θ − θ+
¢
patients purchase it and are subsidized.
9.2. If 0 < c < c∗, P+ does not induce listing.32 In this case, the firm might
choose PLIM = 2(1−η)∆qθ2+η2−2η (the smallest price that induces listing, with an in-
diﬀerent consumer θLIM ) or P = 12 (∆qθ + c) the price that maximizes the no
listing profits. The firm sets P ∗ = PLIM and forces listing if:
θLIM < z or θLIM − θ+ <
?
η
?
(∆qθ)
2−c2(1−η)
?
2∆q
where z is defined as the threshold value of θ that induces listing, this is z ∈
(θ+, θ) such that πL(z) = πNL∗ = 14∆q (∆qθ − c)2.
32Note that c∗ > 0 only if 0≤ η ≤ 0.42. Hence if 0.42 ≤ η we have that c∗ < 0 and only
case 9.1 is relevant.
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An illustration of the proposition is provided in Figure 7. Case 9.2 occurs
when θ+ < θLIM , this is when P+ does not result in a listing outcome. In the
figure, it can be seen that if the ’indiﬀerent consumer’ θLIM falls to the right of
z, the profits achieved with listing are smaller than the maximum profits that
could be achieved with no listing.
(insert figure 7 around here)
Corollary 10 A numerical simulation indicates that for c = 0, if η is smaller
than approximately 0.2, the firm will choose P = 12(∆qθ + c) and not induce
listing, otherwise the firm will choose PLIM and induce listing.
5 Comparison of commitment and non commit-
ment outcomes
In this section we compare the outcome with price commitment with the out-
come described in lemma 6 (non price commitment). The following table sum-
marises the comparison for all cases33.34
(insert Table)
The table confirms the intuition that the firm’s price commitment results in
more listing. This is due to the eﬀect of an ex ante high price choice which in-
duces a listing outcome. In most circumstances (cases b, d and e1) this benefits
the firm who will commit to such high prices. However, if the subsidy is high
and the cost is large (case c), the commitment of the firm results in a reduc-
tion of profits. The reason for this is that in this case in the absence of price
commitment the drug would be listed anyway and there would be no rationing
of the patients who can access it with a subsidy. Instead, with commitment as
the price is higher, the agency rations the number of patients who have reim-
bursement rights and therefore the profits of the firm are smaller. In this case
the firm will not commit to a price.
The comparison of the objective functions for the agency under commitment
and no commitment tells the other side of the story. If the subsidy is small or
if it is high but the costs of production are small, the absence of commitment
favours the agency (these are cases b, e1 and partly d). If instead the subsidy
is large and the production costs are large the commitment favours the agency.
33 In the appendix we show that 2∆qθ?
η+
√
7η2+2η
? > c∗.
34 In this table we report the outcome where c∗ > 0 (which can happen only if 0 ≤ η ≤ 0.42).
If 0.42 ≤ η, all cases in the table stay as they are but cases e and f are not relevant and
should be ignored.
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6 Discussion of results
In this section we discuss the sensitivity of our results to some of the assumptions
which have been made. The main model considers a situation where (a) buyers
with no reimbursement rights can buy the drug privately, (b) the agency can
grant reimbursement rights to a specific group of patients of an illness, according
to the health benefits of the drug on this group and (c) firms cannot price
discriminate between buyers with and without reimbursement rights. In what
follows, we analyze the impact of dropping each of these assumptions.
6.1 Non-existence of an unsubsidized demand for the drug.
The model does not assume that there is a private market, but allows for its
existence. Indeed, in many of the equilibrium results there is no private market
for the drug and only patients with reimbursement rights purchase it. This
happens whenever θF > θL , (drugs are too expensive).
However, one could think of a situation where some exogenous restraint
makes it impossible for patients to purchase the drug privately35 . In such cases,
an extension of the main work results tells us that the agency will list more
frequently. Since there is no private demand, the need to subsidize the drug
arises, even with no externalities in consumption, because of the need to realise
private health benefits36 .
Another diﬀerence accrues with price commitment. Since there is no private
demand for the drug, the value of committing to a high price by the firm to
’force’ a listing outcome does not exist anymore. Here, the price that the firm
chooses does not aﬀect private demand, which always takes a value of 0. Hence,
choosing a high price will only diminish the possibilities that the drug is listed.
6.2 No partial coverage option
We now consider a situation where the agency cannot distinguish a group of
patients and grant those reimbursement rights. In this case, the reimbursement
decision is ”all or none”.
Here, the results in Section 3 (no price commitment) still apply. Despite
that with in Section 3 the agency could chose to distinguish a specific group of
patients, the agency’s reimbursement decision turned out to be ”all or none”-
this is, to reimburse no patients or to reimburse all the patients who would
purchase the drug with the subsidy.
For the case of price commitment and low subsidies, the results in section
4.2.1 continue to apply. It could still be profitable for the firm to set a price
that would induce listing. The reason is that, as before, in section 4.2.1, the
35Not because drugs are too expensive,as this is already incorporated in the main model,
but because of an exogenous restriction such as doctors not being allowed to prescribe drugs
to consumers without reimbursement rights.
36Proofs of this can be obtained from the authors by request.
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decision of the agency is either to reimburse no-one or all the patients who would
purchase the drug with the subsidy.
The only diﬀerence between the results obtained previously and the results
in the case of an ”all or none” decision accrues in the case of price commitment
and high subsidies (figure 6, section 4.2.2), where sometimes the agency decided
to reimburse a group of patients. If the agency can not distinguish a group
of patients, it will chose to reimburse nobody as it is simply too expensive to
subsidize all patients.
6.3 Price discrimination
Price discrimination refers to the ability of the monopoly to set a price for
patients with reimbursement rights, PR and a price for patients with no re-
imbursement rights, PF . With price discrimination the firm has more ”tools”
to extract the rents of the consumer and the agency, and as a consequence, if
anything, price discrimination can only result in more profits.
However, since patients with reimbursement rights can always buy the drug
at full price if they want to, price discrimination can only eﬀectively take place
if the drug’s full price exceeds the price paid by consumers with reimbursement
rights. This is if PF > S = τ + ηPR. This sets a strong constraint on the
firm’s use of price discrimination to obtain more profits, as in our model, the
patients who have smallest willingness to pay are precisely those who have no
reimbursement rights and must pay the high price PF .
Since we must have PF > S, we find that θ
R = S−c∆q < θ
F = PF−c∆q . Hence,
with no price commitment the demand function of the drug is as in expression 2
and figures 3 and 4 would still apply. As a consequence, the agency may choose
not to list (and then only PF matters), or to list and reimburse all patients who
would purchase the drug with a subsidy (and then only PR matters). Therefore,
the results are the same as the ones obtained in Section 3. An intuition is the
following: The monopoly will only price discriminate if this is more profitable.
Yet, to price discriminate, the firm must set a higher price for consumers with no
rights, precisely those with the smallest willingness to pay for the drug. This re-
striction implies that the firm can not make more profit by price discriminating,
and explains why the results in Section 3 do not change.
With price commitment, since PF > S and θ
R < θF the problem for the
agency is to choose the listing threshold as described in expression (6) (where P
is substituted by PR). Figures 5 and 6 remain unchanged. As in the situation
with no price discrimination, by setting a high PF , there will be a further
incentive for the agency to list. Yet, with price discrimination this is easier to
accomplish for the firm, as now, increasing PF only increases the excess health
benefits of listing but does not directly raise the financial costs of listing which
depend on PR. If profitable, the firm could raise PF and keep the price with
reimbursement at a certain level.
In the case with low subsidies and no price discrimination we obtained that
the company achieved the highest possible profits, associated with θR∗ (see
19
section 4.2.1). Price discrimination can not improve on this, and hence, the
results in section 4.2.1 remain unaltered.
In the case of high subsidies and no price discrimination (section 4.2.2), the
price that maximized profits when some patients held reimbursement rights was
PR = P+. When P+ is high enough to induce listing, the firm does not need
to price discriminate in order to achieve this outcome (then, proposition 9.1
still holds). The main diﬀerence with the situation with no price discrimination
takes place if P+ is not high enough to induce listing. With price discrimination,
it will be easier to induce listing by raising PF . For example, the situation with
maximum incentives for reimbursement would be a situation where PF is so
high that no-one would purchase the drug privately. In these circumstances,
the agency would need to compare the objective function when P = P+ with
the situation with no sales of the private drug.
As a consequence, we obtain that, in most circumstances, price discrimina-
tion does not aﬀect the results obtained and, when it does, it results in more
listing.
7 Conclusions
This paper identifies the eﬀects of the strategic interaction between a govern-
ment agency making decisions to subsidize consumption of drugs based on how
eﬀective these drugs are on diﬀerent patient groups and firms making decisions
about drug prices. We focus the analysis on the costs of drug provision, a
relatively under-researched area, as most of the literature has considered the
measurement of health benefits and its monetary value. Our remit is to make
two simple points about this cost:
1. The cost of provision can not be based on historical prices and sales as the
reimbursement decision may have an impact on market prices and quantities.
A prospective analysis is needed.
2. Because of the former, it is crucial to understand how drug prices are set,
and how firms react to and anticipate ”reimbursement news”.
The paper deals with these two points in a specific setting. The main analy-
sis is based on a situation where patients can purchase the drug at full price
if they have no reimbursement rights, where the pharmaceutical firm is free to
choose prices but can not price discriminate between subsidized and unsubsi-
dized consumers, and where the agency chooses a level of coverage (or group
of consumers to subsidize) taking into consideration the excess health benefits
of doing so (including private benefits and externalities) and balancing those
against the excess public costs. In the model, the agency chooses an eﬀective-
ness threshold, and patients who fall in this range are subsidized.
In our benchmark scenario, the agency takes the listing decision first and
then the firm chooses the price. Here, the main reason for listing the drug for
reimbursement is to expand the benefits of the drug to consumers who would
not purchase it privately, despite the public cost. Given the agency’s aim of
reducing public costs, subsidizing a few needy consumers makes no sense if those
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consumers would have purchased the drug at full price. Hence, the agency’s
decision will be either to subsidize no patients at all, or to subsidize some, but
in this case it will give reimbursement rights as well to patients who would
not have purchased the drug at full price.37 It pays to do this whenever the
private and public benefits from drug consumption really diverge- this is when
consumers purchase too little privately. This might happen for several reasons:
(i) patients are not willing to pay for the drug, but there are large externalities
of them consuming the drug and (ii) the diﬀerence in costs between the new
drug and the alternative treatment is large. Indeed, if there is the diﬀerence
between the costs is small and there is no externality, the agency reimburses no
consumers. It is also interesting to note that if the subsidy is high, the more
eﬀective the new drug is (higher quality), the fewer are the incentives to list it.
The reason for this is that as the quality increases, the patients are more willing
to purchase the drug privately.
In a second scenario, we study what the outcome would be if the firm could
commit to a price before the agency decided on the listing decision. We prove
that in this situation, for most parameter configurations, the firm decides to
increase prices as this is a means to induce listing. The mechanism is the
following: by committing to a high price ex ante, the firm is ”promising” small
consumption levels if there is no reimbursement. If the promise is credible, the
agency is more willing to reimburse. We do not identify in the paper what
makes the promise credible, but we note that regulations which imply some
stickiness in prices will make those commitments possible. This is the case with
the UK regulation for drug prices, the Pharmaceutical Price Regulation Scheme,
which allows initial free pricing for a drug but then makes prices very diﬃcult
to change.
Our model can be extended to analyze other cases. In particular, the case
when firms can price discriminate between consumers who have or do not have
reimbursement rights and the case that the agency cannot distinguish specific
groups of patients and must reimburse all patients or none. In both cases,
the main results are only aﬀected if subsidies are large and firms can commit to
prices. In these circumstances, price discrimination makes listing more probable,
but the inability of the agency to distinguish sub-groups of patients makes listing
less probable.
Our model considers a world of mixed public/private provision of health
care where patients can purchase drugs privately. Alternatively, with no pri-
vate demand, listing would be more probable, as in the main model one of
the motivations for the agency not to list is that some patients would buy the
drug even with no subsidy. Also, with no private demand, committing to high
prices would not result in a smaller private demand ex post. As a consequence,
promises of high prices, only result in a larger public unit cost and hence, a
smaller probability of listing.
Finally, in this paper we have assumed that all consumers have the same or
37This is, in the end, the choice of an optimal coverage level, boils down to a binary decision:
either the agency does not list, or it lists and gives reimbursement rights to a ”large” amount
of patients.
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similar income (no patient is income constrained) and that the variation in their
willingness to pay for the drug is only linked to health eﬀects. In addition, we
have not considered the insurance role of public health subsidies.
Although restrictive, these assumptions can be justified within the context
of this paper’s objective. Our aim is only to analyze the interaction between an
agency that decides on listing and a firm setting prices for the drug. The level of
subsidy is exogenous and not decided by the agency. Our observation is that in
many countries, the subsidy level and which social group is entitled to a subsidy
(level of income, age or status) is decided by parliament, precisely with the aim
of homogenizing purchasing power when it comes to health markets. However,
the listing decision and the decision on which specific groups of patients should
have subsidized access to drugs is delegated to a separate agency, that advises
doctors on who to prescribe drugs. This is reasonable, as there are many new
drugs and the degree of detail and types of analysis that these decisions need
cannot be undertaken in a general law. Moreover, given the costs that new
drugs impose on public health systems, one can also think that the reason to
delegate the decision stems from an idea that the agency will be cautious in its
decision making, and will not take into consideration non-health benefits of the
drug access.
To continue, our results will be fully operational in circumstances where
there is a strong correlation between the occurrence of an illness and income
levels, so that the patients suﬀering from the illness have similar income38. If
this was not the case, we would find that for certain price levels, the demand
of either group would vary. This is, some consumers who would be equally ill,
but would be poorer, would not purchase the drug at full price (and perhaps at
the reimbursed price). This would create more kinks in the demand function,
(and discontinuities in the profit and objective function) further complicating
the analysis.
Concluding, as mentioned in the introduction, health care provision is highly
jurisdiction specific. Because of this, the analysis of the interaction between
diﬀerent agencies setting prices, degree of coverage and other related variables
is an interesting future line of research.
38Clearly, also if the income level of the population is similar.
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8 Appendix
Section 3.1: Full derivation of the firm’s demand function.
Since θF > θR, there are 3 regimes:
Regime 1, (θL < θR): The demand of patients with reimbursement rights is
DR = θ − θR. There is no demand of patients with no reimbursement rights.
Regime 2, (θR < θL < θF ): The demand of patients with reimbursement
rights is DR = θ − θL. There is no demand of patients with no reimbursement
rights.
Regime 3, (θF < θL): The demand of patients with no reimbursement rights
is DF = θL − θF . All patients with reimbursement rights purchase the drug:
DR = θ − θL.
Finally the demand function is:
D =
(
min
n
θ − θR, θ − θL
o
if θF > θL
(θ − θL) + (θL − θF ) = θ − θF if θF < θL
Proposition 2.
We start by finding optimal decisions of the firm for each coverage regime:
Regime 1, (θL < θR): The profit maximization problem is:
max
{θR}
h
πR(θ
R) = 1η
³
∆qθR + c− τ − ηc
´³
θ − θR
´i
such that θR>θL. The in-
terior solution is θR∗ = ∆qθ+ηc+τ−c2∆q and PR =
1
2η
¡
∆qθ + c+ η · c− τ¢ . The
value of profits at this solution is: π∗R =
1
4η∆q
¡
∆qθ − ηc− τ + c
¢2
. Note that
θR∗ > θL implies that θ2 +
ηc+τ−c
2∆q > θL (condition A1).
Regime 2, (θR < θL < θF ): The profit maximization problem is:
max
{P}
£
πL(θL) = (P − c)
¡
θ − θL
¢¤
. Since πL(θL) is increasing in P , the op-
timal price is the largest price that guarantees that consumer θL purchases
the drug. Hence: PL =
θL∆q+c−τ
η . The value of profits at this solution is
π∗L =
θL∆q+c−τ−ηc
η
¡
θ − θL
¢
.
Regime 3, (θF < θL): The profit maximization problem is:
max
{θF}
h
πF (θ
F ) =
³
∆qθF + c− c
´³
θ − θF
´i
such that θF ≤ θL. The solution is
PF = 12
¡
∆qθ + c+ c
¢
and θF∗ = ∆qθ+c−c2∆q . The profits evaluated at this solu-
tion are: π∗F =
1
4∆q
¡
∆qθ + c− c
¢2
. Note that θF∗ ≤ θL is satisfied if ∆c2∆q < θL
(condition A3).
Boundary Conditions
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An interior solution in Regime 1 (respectively, Regime 3) requires A1 (A3) to
hold. If A1 (A3) is not satisfied, the corner solution for the regime is a price
such that θR = θL, (respectively, θ
F = θL). This corner solution yields profits of
πR(θL) = 1η (∆qθL + c− τ − ηc)
¡
θ − θL
¢
,
¡
πF (θL) = (∆qθL + c− c)
¡
θ − θL
¢¢
.
Note that, θR∗ < θF∗ since τ/(1− η) < c < ∆qθ. Hence, A1 and A3 are incom-
patible. If one holds, the other does not. Note also that if, θF∗ < θL < θ
R∗
neither θF∗ nor θR∗ are valid solutions. As a consequence we can establish the
candidate solutions for each of the following cases:
Case 1. If θL > θ
R∗ we must compare: πR (θL) , π∗L and π
∗
F .
Case 2. If θF∗ < θL < θ
R∗ we must compare: πR (θL) , π∗L, and πF (θL) .
Case 3. If θL < θ
F∗, we must compare: π∗R, π
∗
L and πF (θL).
Since πR (θL) = π∗L > πF (θL) ,in Case 2 the global solution is π
∗
L. For
the other cases, the comparison simplifies to: Case 3. {π∗R, π∗L} , and Case 1.
{π∗L, π∗F }.
In Case 3 the global solution is π∗R since π
∗
R > πR (θL) = π
∗
L.
In Case 1 we obtain that there exists an α, with α > θR∗ such that if θL > α
then the global solution is π∗F . Otherwise, the global solution is π
∗
L. The value
of α is:
α = θR∗ +
?
(∆qθ+ηc+τ−c)2−η(∆qθ+c−c)2−4∆qθ(τ+ηc−c)
2∆q .
The proof of this last result is in three steps:
Step 1. If θL = θ, then π∗L = 0 and π
∗
F − π∗L > 0.
Step 2. π∗F −π∗L = 14∆q
¡
∆qθ + c− c
¢2− 1η ¡θ − θL¢ (∆qθL + c− τ − ηc) . Then:
∂(π∗F−π∗L)
∂θL
= − 1η ·
¡
−2∆q · θL +∆qθ + ηc+ τ − c
¢
= 2∆qη ·
³
θL − θR∗
´
. A3 im-
plies that ∂(π
∗
F−π∗L)
∂θL
> 0.
Step 3. Finally, we find α, defined as the value θL such that θL > θ
R∗ and
π∗F − π∗L = π∗F − πR(θL) = 0. Note that: π∗F − π∗L = 0 implies that:
θ2L∆q−θL
£
∆qθ + ηc+ τ − c
¤
+
h
η
4∆q
¡
∆qθ + c− c
¢2
+ θ (τ + ηc− c)
i
= 0. This
is:
θπ
∗
F=π
∗
L
L =
[∆qθ+ηc+τ−c]±
?
(∆qθ+ηc+τ−c)2−4∆q
? η
4∆q (∆qθ+c−c)
2
+θ(τ+ηc−c)
?
2∆q =
θR∗ ±
r³
θR∗
´2
− η(∆qθ+c−c)
2
+4∆qθ(τ+ηc−c)
(2∆q)2
.
Since α > θR∗, we eliminate the negative root: α is the positive root. Finally,
we show that α > θF∗. Recall that: (i) θF∗ maximizes π∗F , (i) θ
R∗ maximizes
π∗R, (iii) for any z, πR (z) > πF (z) and (iv) θ
R∗ < min{α, θF∗}. Assume that
α < θF∗.Then there exists a z, such that α < z < θF∗ and πR (z) = πF (z) .
This contradicts (iii).
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Section 3.3: Analysis of the objective function.
The value of the objective function is:
OF (θL) =
⎧
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
OF1 =
qθ
2
2 −
θ2
2 −
∆qθR∗
2
2 −
θ−θR∗
2η . (1− η) (∆q θ + c+ ηc)−
− (1 + η) τ + v
³
θ − θR∗
´
if θL < θ
R∗
OF2 =
qθ
2
2 −
θ2
2 −
∆qθ2L
2 −
1
η ·
¡
θ − θL
¢ · ((1− η) (c+∆qθL)− τ)+
v
¡
θ − θL
¢
if θR∗ < θL < α
OF3 =
qθ
2
2 −
θ2
2 −
∆qθF∗
2
2 −
θ−θL
2
³
(1− η)
³
c+∆qθF∗ + c
´
− 2τ
´
+
+v
³
θ − θF∗
´
if θL > α
Shape of the objective function.
Note that θF∗ and θR∗ do not depend on θL. As a consequence, OF1 is constant
in θL and OF3 is increasing in θL.
We now study the shape of OF2. Note that:
∂OF2
∂θL
= −∆qθL + 1η ((1− η) (c+∆qθL)− τ)−
1−η
η ∆q
¡
θ − θL
¢
− v.
Thus, ∂OF2∂θL = 0 if θL = θ
MIN
L =
(1−η)(∆qθ−c)+τ+vη
(2−3η)∆q .
Note also that: ∂
2OF2
∂θ2L
= −∆q + 1−ηη ∆q +
1−η
η ∆q = ∆q
2−3η
η .
Therefore:
a. If η < 23 ,
∂2OF2
∂θ2L
> 0 and θMINL ∈ (θR∗, α) is a minimum for OF2.
b. If η > 23 ,
∂OF2
∂θL
< 0 and ∂
2OF2
∂θ2L
< 0. OF2 is decreasing and convex in
θL ∈ (θR∗, α). To see this, note that since η >
2
3
and ∆qθ− c > 0 we have that
2−3η
η ∆qθL−
1−η
η
¡
∆qθ − c
¢
< 0, which implies that 1−ηη 2∆qθL−∆qθL+
1−η
η c−
1−η
η ∆qθ < 0, i.e.:
∂OF2
∂θL
< 0.
Finally, we note that OF1 = OF2(θ
R∗), i.e., OF is continuos at θR∗. However,
OF has a discontinuity at α.
Lemma 4. The following expression is the diﬀerence in payoﬀs between listing
and not listing:
∆q
2 ·
µ³
θF∗
´2
−
³
θR∗
´2¶
+v
³
θF∗ − θR∗
´
−(θ−θR∗)
³
1−η
η (∆qθ
R∗ − τ + c)− τ
´
which after some algebra we can rewrite as:
1
4∆q · [(c(1− η)− τ)(∆qθ + 2v) + c2/2(1 + 2η)− 3/2 · (cη + τ)2−
1
η (∆qθ + c− τ)2 + (∆qθ + c)2 − c(c(1− η)− τ))]
Then:
∂OF1(θL)−OFNL
∂v =
1
2∆q (c(1− η)− τ)) > 0.
∂OF1(θL)−OFNL
∂c =
1
4∆q [(1− η) · (∆qθ + 2v) + c(1 + 2η − 3η2)− 3ητ−
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(1− η) c] =
= 14∆q
£
(1− η)
¡
∆qθ + 2v + c− c
¢
+ 3η · ((1− η) c− τ)¤ > 0.
∂OF1(θL)−OFNL
∂c = −
1
η (∆qθ + c− τ) + (∆qθ + c)− (c(1− η)− τ)) =
− 1η [(∆qθ+ c)(1− η)− τ ]− (c(1− η)− τ)) < 0, since τ < (1− η) · (∆qθ+ c).
Lemma 5.
Note that the denominator of OF1 (θL)−OFNL is increasing in ∆q. Define the
numerator of the OF1 (θL)−OFNL as: Num(∆qθ) = (c(1−η)−τ)(∆qθ+2v)+
c2/2(1 + 2η)− 3/2 · (cη + τ)2−
1
η (∆qθ + c− τ)2 + (∆qθ + c)2 − c(c(1− η)− τ)).
Changes in ∆q and θ have an identical eﬀect on Num(∆qθ). If Num(∆qθ)
is decreasing in ∆qθ, then OF1 (θL) − OFNL is decreasing in ∆q and θ. If
Num(∆qθ) is increasing in θ then OF1 (θL) − OFNL is increasing in θ. We
check under which conditions Num(∆qθ) is decreasing in ∆qθ.
∂Num(∆qθ)
∂(∆qθ)
= (c(1− η)− τ)− 2η (∆qθ + c− τ) + 2(∆qθ + c) =
1
η [η(c(1− η)− τ)− 2(∆qθ + c− τ) + 2η(∆qθ + c)] =
= 1η [η(c(1− η)− τ)− 2(1− η)∆qθ − 2((1− η)c− τ)].
If this last expression is negative, then Num(∆qθ) is decreasing in ∆qθ. How-
ever, note that ∂Num(∆qθ)
∂(∆qθ)
can have either a negative or a positive sign. For
example, if η = 0, then ∂Num(∆qθ)
∂(∆qθ)
→ limη→0[ 1η [−2∆qθ − 2[c − τ ]] < 0 and if
η = 1, then ∂Num(∆qθ)
∂(∆qθ)
= [−ητ + 2τ ] > 0. Indeed ∂Num(∆qθ)
∂(∆qθ)
is increasing in η :
∂
∂η
³
∂Num(∆qθ)
∂(∆qθ)
´
= −c+ 2(∆qθ + c− τ)/η2 = 2(∆qθ+c−τ)−η
2c
η2 > 0.
Hence, for small values of η we obtain that ∂Num(∆qθ)
∂(∆qθ)
< 0 and for large values
of η, ∂Num(∆qθ)
∂(∆qθ)
> 0.
Lemma 6.
Here:
OF1 (θL)−OFNL =
= 14∆q [c(1− η)(∆qθ) + c2/2(1 + 2η)− 3/2 · (cη)2 − 1η (∆qθ)2 + (∆qθ)2)] =
= 14∆qη [−(1− η)(∆qθ)2 + (1− η)η∆qθc+ c2/2(η + 2η2 − 3η3)] =
= (1−η)4∆qη [−(∆qθ)2 + ηc∆qθ + c2/2(η + 3η2)].
Hence, if −(∆qθ)2 + ηc∆qθ + c2/2(η + 3η2) < 0 then OF1 (θL)−OFNL < 0.
Studying the last expression we obtain that OF1 (θL) − OFNL < 0 is negative
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if ∆qθ exceeds c/2(η +
p
7η2 + 2η) (the positive root of the polynomial). Note
that c/2(η +
p
7η2 + 2η) is increasing in η. Hence, OF1 (θL) − OFNL is least
likely to be negative when η = 1. Note that in this case c/2(η +
p
7η2 + 2η)
= 2c. In conclusion, if ∆qθ > 2c = maxη{c/2(η +
p
7η2 + 2η)}, 0 ≤ η < 1,
then ∆qθ > c/2(η +
p
7η2 + 2η) for all η, 0 ≤ η < 1, and we can conclude that
OF1 (θL)−OFNL < 0.
Section 4: Price commitment. Local maximization of OF with respect
to θL.
We start by finding the value of θL that maximizes each region of OF .
1. θL < θR. Here: OF1 = q θ
2
2 −
θ2
2 −∆q
θR
2
2 −(1− η)P
³
θ − θR
´
, and ∂OF1∂θL = 0.
Therefore, the agency is indiﬀerent between any θL, for any θL ∈ (θ, θR)
2. θR < θL < θF . Here: ∂OF2∂θL = −∆qθL + (1− η)P = 0 ⇒ θ
ˆ = (1−η)P∆q and
∂2OF2
∂θL
= −∆q < 0. Hence: OF ∗2 = q θ
2
2 −
θ2
2 −∆q
θˆ2
2 − (1− η)P
³
θ − θˆ2
´
.
Note that θF > θˆ > θR implies that ηP < (1− η)P < P . If η < 1/2, we
have that θF > θˆ > θR but if η > 1/2, we have that θF > θR > θˆ, which
invalidates OF ∗2 as a solution as consumer θ
ˆ does not purchase the drug.
3. θF < θL. Here:
∂OF3
∂θL
= (1− η)P > 0 ⇒ θ∗3L = θ and OF ∗3 = q θ
2
2 −
θ2
2 −
∆q θ
F2
2 .
Proposition 7.
1. η > 1/2. We compare OF ∗1 and OF ∗3 :
OF ∗1 −OF ∗3 =
µ³
θF
´2
−
³
θR
´2¶
− P (1− η)
³
θ − θR
´
=
³
θF − θR
´³
θF + θR
´ ∆q
2
−P (1− η)
³
θ − θR
´
= (1−η)∆q P
³
(1+η)P
2 −
¡
∆qθ − ηP
¢´
.
Note that (1−η)∆q P
³
(1+3η)P
2 −∆qθ
´
> 0 iﬀ P > 2∆qθ(1+3η) .
Recall that ηP < ∆qθ. This condition is compatible with P > 2(1+3η)∆qθ as
2η − 3η < 1.
2. η < 1/2. We compare OF ∗2 and OF
∗
3 :
OF ∗2 −OF ∗3 =
∆q
2
µ³
θF
´2
−
³
θˆ
´2¶
− (1− η)P
³
θ − θˆ
´
=
∆q
2
³
θF + θˆ
´³
θF − θˆ
´
− (1− η)P
³
θ − θˆ
´
=
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P
∆q
µ
1
2
(2− η)Pη − (1− η)
¡
∆qθ − (1− η)P
¢¶
> 0.
Note that OF 2∗ −OF 3∗ > 0 iﬀ P > (1−η)∆qθ22+η2−2η .
Recall that ηP < ∆qθ. This last condition is compatible with P > (1−η)∆qθ22+η2−2η
since η < 12 implies that
2(1−η)
2+η2−2η <
1
η .
Proposition 8.
If the drug is listed for reimbursement the firm’s profits are: (P − c)(θ− θR) =
(P − c)(θ− ηP∆q ). These profits are maximized when P ∗ =
∆qθ+ηc
2η . Their value is
1
4η∆q (∆qθ−ηc)2. This value exceeds the maximum value of the profits achieved
with no reimbursement: 14∆q (∆qθ − c)2. Moreover, P ∗ =
∆qθ+ηc
2η >
2∆qθ
1+3η , since
∆qθ (1− η) + η (1 + 3η) c > 0. This implies Proposition 8.
Proposition 9.
Recall that for η < 12 , if P > P
LIM the agency sets θ∗L =
(1−η)P
∆q , but if
P < PLIM , the agency sets (θL = θ). For P+ to encourage listing, it must be
that P+ > PLIM , this is that c > ∆qθ
³
2−6η+3η2
(1−η)(2+η2−2η)
´
. If this last inequality
holds, Proposition 9.1 follows.
However, if c < ∆qθ
³
2−6η+3η2
(1−η)(2+η2−2η)
´
, P+ does not induce the agency to list the
drug and the firm’s optimal choice will either be PLIM (which induces listing)
or 12
¡
∆qθ + c
¢
, which maximizes the profit with no listing (πF ). Proposition
9.2 provides the condition under which PLIM is best. The following steps yield
such condition.
Step 1 : We define the profits of no listing (θL = θ) and of listing (θL = θ
∗
L)
as a function of the indiﬀerent consumer I. With no listing I = P/∆q so:
πNL [I] = (∆qI − c)
¡
θ − I
¢
. With listing, I = θ∗L = (1 − η)P/∆q so: πL [I] =
(P − c)
¡
θ − I
¢
=
1
1− η (∆qI − (1− η)c)
¡
θ − I
¢
.
Step 2 : We proof that for any fixed I ∈ [0, θ), πL [I] > πNL [I] .39 Note that:
πL − πNL = ( 11−η (∆qI − (1− η)c) − (∆qI − c))
¡
θ − I
¢
. Hence if θ > I, then
πL − πNL > 0.
Step 3 : We define z as the value of θ that induces listing, this is z ∈ (θ+, θ) such
that πL(z) = πNL∗ = 14∆q (∆qθ−c)2. Therefore, z is such that:
³
∆qz
(1−η) − c
´ ¡
θ − z
¢
=
(∆qθ−c)
2
4∆q .This equation has two roots:³
∆qθ+(1−η)c
2∆q
´
±
?
η
?
(∆qθ)2−c2(1−η)
?
2∆q = θ
+ ±
?
η
?
(∆qθ)2−c2(1−η)
?
2∆q .
39 If
−
θ = I, then πNL [I] = πL [I] .
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Note that the smallest root is smaller than θ+, therefore it can not induce list-
ing. Hence, z = θ+ +
?
η
?
(∆qθ)
2−c2(1−η)
?
2∆q . Note for any θ > z, π
L < πNL∗ and
for any θ < z, πL > πNL∗.
Step 4: If the price is PLIM , the indiﬀerent consumer is θLIM = θL
¡
PLIM
¢
=
(1−η)PLIM
∆q =
1−η
∆q
³
2(1−η)∆qθ
2+η2−2η
´
= 2(1−η)
2θ
2+η2−2η . Note that θ
LIM > θ+ since PLIM >
P+ =
c
2
+ ∆qθ2(1−η) .
Step 5: Given steps 3 and 4 we can conclude that: if θLIM < z, then, the firm
will prefer to induce listing and PLIM will be the global maximum. This is the
condition stated in proposition 9.2.
Corollary 10. Note that: θLIM < z ⇔ 2(1−η)
2
−
θ
2+η2−2η−
−
θ
2 <
c(1−η)
2∆q +
????η
??
∆q
−
θ
?2
−(1−η)
?
c2
2∆q ,
which can be rewritten as: ∆q
−
θ 2+3η
2−6η
(2(1−η)+η2)(1−η)−c <
1
1−η
vuutηÃµ∆q−θ¶2 − (1− η) c2!.
The above inequality can revert sign depending on the value of η. For example
if c = 0, the condition simplifies to 2 + 3η2 − 6η −
¡
2 + η2 − 2η
¢√
η < 0.This is
satisfied when η > 0.2.
Section 5.
We first prove that 2∆qθ?
η+
√
7η2+2η
? > c∗. This implies that:
2(1− η)(2 + η2 − 2η)− (η +
p
7η2 + 2η)(2 + 3η2 − 6η) > 0
This expression holds for η = 0 and η = 1/2.Below, we provide a numerical
evaluation of the expression for 0 < η < 1/2:
0.50.3750.250.1250
4
3.5
3
2.5
2
1.5
x
y
The expression has a minimum at η = 0.326. We evaluate the expression in
this point to obtain its positive value 1.4134.
29
Section 5, Table 1: Proof of cases c, d and e
Note that in all these cases η < 12
Case c (comparison of the outcomes with no price commitment
(θR∗) and price commitment (θ+)).
Note that P+ > PR and θ
R∗ < θ+.40 This implies that the demand is larger
with no price commitment and that the price is larger with commitment.
Profit Comparison:
Since π+ = 1−η4∆q
³
∆qθ
1−η − c
´2
and πR∗ = 14η∆q
¡
∆qθ − ηc
¢2
: πR∗ > π+ ⇔
1
4∆q (
1
η
¡
∆qθ − ηc
¢2
> 11−η
¡
∆qθ − (1− η)c
¢2
.This expression holds iﬀ
(1− 2η)((∆qθ)2 − η(1− η)c2) > 0. Since η < 12 and ∆qθ > c we conclude that
πR∗ > π+, i.e.: πNPC > πPC .
Agency’s objective function comparison:
Note that OFNPC = q
θ
2
2
− θ
2
2
−∆q θ
R∗2
2
− (1− η)PR
³
θ − θR∗
´
and
OFPC = q
θ
2
2
− θ
2
2
−∆q θ
+2
2
− (1− η)P+
¡
θ − θ+
¢
.
Hence:
OFPC −OFNPC = ∆q2 (θ
R∗2 − θ+
2
) + (1− η) (PR
³
θ − θR∗
´
− P+
¡
θ − θ+
¢
) =
= ∆q
8(∆q)2
³
(∆qθ + ηc)
2 − (∆qθ + (1− η) c)2
´
+
+ (1− η)
³
∆qθ+ηc
2η
³
∆qθ−ηc
2∆q
´
− ∆qθ+(1−η)c2(1−η)
³
∆qθ−(1−η)c
2∆q
´´
.
Note that if η → 0 then OFPC − OFNPC → +∞.Recall that if η → 1/2,
OFPC−OFNPC → 0.We now prove thatOFPC−OFNPC > 0 for 0 < η < 1. By
simplifying the expression we obtain: ∆qθ (1− 2η) ∆qθ − ηc
η
+
1− 4η (1− η)
2
c2.
To prove this, take the derivative of this expression with respect to c:
−∆qθ (1− 2η) + [1 − 4η (1− η)]c. Since 0 < η < 1/2 and ∆qθ > c, that
this derivative is negative. Hence the expression is least likely to hold for
large c. A suﬃcient condition would be if it held for c = ∆qθ. In this case
OFPC − OFNPC becomes: c2 (1− 2η) 1− η
η
+
1− 4η (1− η)
2
c2. It is posi-
tive whenever (1− 2η) 1− η
η
+
1− 4η (1− η)
2
> 0. This is 2 (1− 2η) (1 − η) +
(1 − 4η (1− η))η > 0 or 0 < 4η3 − 5η + 2. This expression is positive for
0 < η < 1/2.Therefore, OFPC > OFNPC .
Case d. (Comparison of the outcomes with no price commitment
(θF∗) and price commitment (θ+))
Profit Comparison:
40 If η = 1/2, P+ = PR =
c+∆qθ
2
and the two outcomes coincide.
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Since π+ = 1−η4∆q
³
∆qθ
1−η − c
´2
and πF∗ = 14∆q
¡
∆qθ − c
¢2
we obtain that: π+ −
πF∗ = 1−η4∆q
³
∆qθ
1−η − c
´2
− 14∆q
¡
∆qθ − c
¢2
> 0 which clearly holds as:
¡
∆qθ − (1− η)c
¢2
>
(1− η)
¡
∆qθ − c
¢2
Agency’s objective function comparison:
Note that OFNPC = q
θ
2
2
− θ
2
2
−∆q θ
F∗2
2
and OFPC = q
θ
2
2
− θ
2
2
−∆q θ
+2
2
−
(1− η)P+
¡
θ − θ+
¢
. Hence: OFNPC−OFPC = ∆q
2
³
θ+
2
− θF∗
2
´
+(1− η)P+
¡
θ − θ+
¢
.
Substituting the diﬀerent variables and simplifying the expression we get:
OFNPC −OFPC = 1
4∆q
Ã
c
2
η (η − 2)
2
− ηc∆qθ +
¡
∆qθ
¢2 − (1− η)2 c2! =
1
4∆q
³
(η − 12η2 − 1)c2 − ηc∆qθ +
¡
∆qθ
¢2´
Hence OFNPC −OFPC > 0 iﬀ
¡
∆qθ
¢2 − ηc∆qθ − c2 ¡1− η ¡1− 12η¢¢ > 0.
Note that ∂OF
NPC−OFPC
∂c = −η∆qθ − 2c
¡
1− η
¡
1− 12η
¢¢
< 0
Hence, OFNPC−OFPC is decreasing in c if 0 ≤ η ≤ 1/2 and has a maximum
at c = 0, where the expression achieves a positive value of
¡
∆qθ
¢2
. The positive
root of OFNPC −OFPC is
c+ = 1−2η+η2+2
µ
−∆qθη +
q
4(∆qθ)2 − 4(∆qθ)2η + 3(∆qθ)2η2
¶
.
This implies that if c < c+ then OFNPC−OFPC > 0 and otherwise OFNPC−
OFPC < 0.
Recall that in case (d)
∆qθ(2+3η2−6η)
(1−η)(2+η2−2η) ≤ c ≤
2∆qθ
η+
√
7η2+2η
, we check the
relative position of c+ with respect to these two values:
1.
∆qθ(2+3η2−6η)
(1−η)(2+η2−2η) < c
+. This is that:
∆qθ(2+3η2−6η)
(1−η)(2+η2−2η) <
1
−2η+η2+2
µ
−∆qθη +
q
4(∆qθ)2 − 4(∆qθ)2η + 3(∆qθ)2η2
¶
→¡
2 + 3η2 − 6η
¢
< (1− η)
³
−η +
p
4− 4η + 3η2
´
→¡
2 + 3η2 − 6η
¢
+ η(1− η) < (1− η)
p
4− 4η + 3η2 →
2η2 − 5η + 2 < (1− η)
p
4− 4η + 3η2 →
(2η2 − 5η + 2)2 − (1− η)2 (4 − 4η + 3η2) = 18η2 − 8η − 10η3 + η4 < 0 →
18η − 8− 10η2 + η3 < 0.
If η = 0 the expression holds. If η = 1/2, then the expression is−1. 375.
Plotting the expression we find that 18η − 8− 10η2 + η3 is:
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2. c+ < 2∆qθ
η+
√
7η2+2η
. This is that:
1
−2η+η2+2
µ
−∆qθη +
q
4(∆qθ)2 − 4(∆qθ)2η + 3(∆qθ)2η2
¶
< 2∆qθ
η+
√
7η2+2η
→
1
−2η+η2+2
³
−η +
p
4− 4η + 3η2
´
< 2
η+
√
7η2+2η
(η +
p
7η2 + 2η)
³
−η +
p
4− 4η + 3η2
´
< 2(−2η + η2 + 2)→
(η +
p
7η2 + 2η)
³
−η +
p
4− 4η + 3η2
´
− 2(−2η + η2 + 2) < 0→
(η +
p
7η2 + 2η)
³
−η +
p
4− 4η + 3η2
´
− 2(−2η + η2 + 2) < 0
Note that if (η +
p
7η2 + 2η)
³
−η +
p
4− 4η + 3η2
´
− 2(−2η + η2 + 2) = 0
then η = −2. Indeed by plotting this expression we find that
(η +
p
7η2 + 2η)
³
−η +
p
4− 4η + 3η2
´
− 2(−2η + η2 + 2) is:
0.50.3750.250.1250
0
-1
-2
-3
-4
x
y
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If η = 0 then the expression is -4 and if η = 1/2 the expression is −2.
168 4× 10−19
In conclusion we obtain the following: If c ∈ {min(0, ∆qθ(2+3η
2−6η)
(1−η)(2+η2−2η)}, c+}
then OFNPC −OFPC > 0. If c ∈ {c+, 2∆qθ
η+
√
7η2+2η
} then OFNPC −OFPC < 0.
Case e1 (Comparison of the outcomes with no price commitment
(θF∗) and price commitment (θLIM ))
Profit Comparison: See the proof of lemma 10 for reference.
Agency’s objective function comparison: Note that OFNPC = OFNL =
q
θ
2
2
−θ
2
2
−∆q θ
F∗2
2
andOFPC = q
θ
2
2
−θ
2
2
−∆q θ
LIM2
2
−(1− η)PLIM
³
θ − θLIM
´
.
Recall that in case d we have proven that for c < c+ then OFNL − OF+ > 0.
Case e1 is relevant when 0 < c <
∆qθ(2+3η2−6η)
(1−η)(2+η2−2η) (< c
+). Hence in this case we
know that OFNL−OF+ > 0.We now proof that OF+−OFLIM > 0 to conclude
that in case d OFNL −OFLIM > 0 this is that OFNPC > OFPC
Proof that OF+−OFLIM > 0. This entails proving that ∂OF
+(P )
∂P < 0 where
OF+ = q
θ
2
2
− θ
2
2
−∆q θ
+2
2
−(1− η)P
¡
θ − θ+
¢
and θ+ = (1−η)P∆q hence: OF
+ =
q
θ
2
2
− θ
2
2
−∆q
( (1−η)P∆q )
2
2
− (1− η)P
³
θ − ( (1−η)P∆q )
´
; ∂OF
+
∂P = −∆q(
1−η
∆q )
2
P −
(1− η)
³
θ − ( 2(1−η)P∆q )
´
=
−∆q( 1−η∆q )
2
P − (1− η) θ + 2(1−η)
2P
∆q =
(1−η)
∆q
2
P − (1− η) θ.
Hence ∂OF
+
∂P < 0 if
(1−η)
∆q P − θ < 0 this is (1− η)P < ∆qθ. This is satisfied
as θ+ = (1−η)P∆q < θ.
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Figure 8: Table 1: Impact of price commitment on listing decision.
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